A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : MEC / moderately emetogenic chemotherapy

[Related PubMed/MEDLINE]
Total Number of Papers: 81
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   MEC  (>> Co-occurring Abbreviation)
Long Form:   moderately emetogenic chemotherapy
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting in Patients Receiving Moderately Emetogenic Chemotherapy: Results of the Korean South West Oncology Group (KSWOG) Study. CINV, KSWOG, QOL
2019 Adherence to pediatric acute chemotherapy-induced nausea and vomiting guidelines in Canadian hospitals. AGA, CGA, CINV, HEC
2019 Efficacy of the combination use of aprepitant and palonosetron for improving nausea in various moderately emetogenic chemotherapy regimens. PS
2019 Hydration requirements in patients receiving highly emetogenic chemotherapy. GERSC, HEC
2018 Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. 5-HT3RA, CC, CINV, CR, DEX, ESMO, HEC, MASCC, NK1RA, PALO, RCTs
2018 Evaluation of factors contributing to the response to fosaprepitant in a heterogeneous, moderately emetogenic chemotherapy population: an exploratory analysis of a randomized phase III trial. AC, CINV, CR
2018 Hydration requirements with emetogenic chemotherapy: granisetron extended-release subcutaneous versus palonosetron. CINV, GERSC, HEC
2018 Is the addition of a neurokinin-1 receptor antagonist beneficial in moderately emetogenic chemotherapy?-a systematic review and meta-analysis. CINV, CR, NK1RAs, RD
2018 Optimal prophylaxis of chemotherapy-induced nausea and vomiting for moderately emetogenic chemotherapy: a meta-analysis. NK1RA, RR, RRs
10  2018 Recent advances in antiemetics: new formulations of 5HT3-receptor antagonists. ASCO, CINV, GERSC, HEC, NCCN, NK-1
11  2017 Antiemetic Effectiveness and Cost-Saving of Aprepitant plus Granisetron Is Superior to Palonosetron in Gastrointestinal Cancer Patients Who Received Moderately Emetogenic Chemotherapy. ---
12  2017 Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy. CINV, SR
13  2017 Chemotherapy-induced nausea and vomiting (CINV) in 190 colorectal cancer patients: a prospective registration study by the CINV study group of Japan. CINV
14  2017 Chemotherapy-induced nausea and vomiting is less controlled at delayed phase in patients with esophageal cancer: a prospective registration study by the CINV Study Group of Japan. CINV, HEC, VAS
15  2017 Combination of Aprepitant, Azasetron, and Dexamethasone as Antiemetic Prophylaxis in Women with Gynecologic Cancers Receiving Paclitaxel/Carboplatin Therapy. ---
16  2017 Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. APR, CINV, fAPR, HEC, NEPA, NHS, Onda, PALO, QALY
17  2017 Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types. AC, CINV, CR
18  2017 Granisetron transdermal delivery system is effective in the control of chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy (MEC) or highly emetogenic chemotherapy (HEC) in China. HEC
19  2017 Neurokinin-1 Receptor Antagonist-Based Triple Regimens in Preventing Chemotherapy-Induced Nausea and Vomiting: A Network Meta-Analysis. CI, CINV, CRs, HEC, NK1RAs, OR, TRAEs
20  2017 Olanzapine for chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. CINV, HEC, RCTs
21  2017 Prevention of chemotherapy-induced nausea: the role of neurokinin-1 (NK1) receptor antagonists. AC, CIN, HEC, NK-1, RAs
22  2017 Rikkunshito for Preventing Chemotherapy-Induced Nausea and Vomiting in Lung Cancer Patients: Results from 2 Prospective, Randomized Phase 2 Trials. CINV, CR, HEC, UMIN
23  2017 Rolapitant improves quality of life of patients receiving highly or moderately emetogenic chemotherapy. AC, CINV, FLIE, HEC
24  2016 A phase II, randomized study of aprepitant in the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapies in colorectal cancer patients. CINV, CR, CRC
25  2016 A prospective observational study on chemotherapy-induced nausea and vomiting (CINV) in patients with gynecologic cancer by the CINV Study Group of Japan. CINV, GLM, HEC, OR
26  2016 Clinical Practices and Outcomes on Chemotherapy-Induced Nausea and Vomiting Management in South Korea: Comparison with Asia-Pacific Data of the Pan Australasian Chemotherapy Induced Emesis Burden of Illness Study. 5HT3-RA, AP, ASCO, CINV, HEC, PrACTICE, QOPI
27  2016 Comparison of the Control of Nausea and Vomiting among Several Moderately Emetic-Risk Chemotherapy Regimens. CINV
28  2016 Control of chemotherapy-induced nausea in patients receiving outpatient cancer chemotherapy. A/C, HEC
29  2016 Efficacy and safety of rolapitant for prevention of chemotherapy-induced nausea and vomiting over multiple cycles of moderately or highly emetogenic chemotherapy. CINV, HEC, RA
30  2016 Gaps exist between patients' experience and clinicians' awareness of symptoms after chemotherapy: CINV and accompanying symptoms. CINV, HEC, MAT
31  2016 Granisetron Extended-Release Injection: A Review in Chemotherapy-Induced Nausea and Vomiting. CINV, ER, HEC
32  2016 New therapies for antiemetic prophylaxis for chemotherapy. CINV, HEC, NK1RA
33  2016 Should clinicians always administer dexamethasone beyond 24 h after chemotherapy to control delayed nausea and vomiting caused by moderately emetogenic regimens? Insight from the re-evaluation of two randomized studies. AC, CP
34  2016 Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy: results of a randomized, double-blind phase III trial. CINV, CR, i.v, NK-1, RAs
35  2016 Transdermal granisetron for the prevention of nausea and vomiting following moderately or highly emetogenic chemotherapy in Chinese patients: a randomized, double-blind, phase III study. CC, CINV, GTDS, HEC
36  2016 Transdermal granisetron versus palonosetron for prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: a multicenter, randomized, open-label, cross-over, active-controlled, and phase IV study. 5-HT3RA, CINV, CR, FLIE, GTDS
37  2015 A randomized study of the efficacy and safety of transdermal granisetron in the control of nausea and vomiting induced by moderately emetogenic chemotherapy in Korean patients. CINV, CR, FLIE, GTS
38  2015 Delayed chemotherapy-induced nausea and vomiting in autologous hematopoietic cell transplant patients: an exploratory analysis. CINV, HCT, HEC, NV
39  2015 Efficacy of palonosetron and 1-day dexamethasone in moderately emetogenic chemotherapy compared with fosaprepitant, granisetron, and dexamethasone: a prospective randomized crossover study. CC, CR, CT, DEX, fAPR, GRAN, PALO
40  2015 Incidence of chemotherapy-induced nausea and vomiting with moderately emetogenic chemotherapy: ADVICE (Actual Data of Vomiting Incidence by Chemotherapy Evaluation) study. ---
41  2015 Netupitant/Palonosetron: A Review in the Prevention of Chemotherapy-Induced Nausea and Vomiting. AC, CINV, HEC, NEPA
42  2015 Open-label, randomized, comparative, phase III study on effects of reducing steroid use in combination with Palonosetron. AC, CI, CINV, CR, DEX, PALO
43  2015 Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer. CR
44  2015 Prevention and management of chemotherapy-induced nausea and vomiting. CINV, NK-1, QOL
45  2015 Resource Utilization for Chemotherapy-Induced Nausea and Vomiting Events in Patients with Solid Tumors Treated with Antiemetic Regimens. AC, CINV, HEC, NK-1
46  2015 Testing the effectiveness of antiemetic guidelines: results of a prospective registry by the CINV Study Group of Japan. CINV, HEC
47  2015 Therapeutic and preventive antiemetic effect of aprepitant in Japanese patients with thoracic malignancies who truly need it. CINV, HEC, NK-1
48  2015 Usefulness of antiemetic therapy with aprepitant, palonosetron, and dexamethasone for lung cancer patients on cisplatin-based or carboplatin-based chemotherapy. CINV, CR, HEC
49  2014 Adherence to antiemetic guidelines in patients with malignant glioma: a quality improvement project to translate evidence into practice. 5-HT3-RAs, CINV, DEX, NCCN, PAL, PRTBTC, QOL
50  2014 Effectiveness of palonosetron for preventing delayed chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy in patients with gastrointestinal cancer. ---
51  2014 Multicenter phase IV study of palonosetron in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with non-Hodgkin lymphomas undergoing repeated cycles of moderately emetogenic chemotherapy. CINV, NHL, RA
52  2014 Olanzapine for chemotherapy-induced nausea and vomiting: a systematic review. CINV, HEC, RCTs
53  2014 Palonosetron versus older 5-HT3 receptor antagonists for nausea prevention in patients receiving chemotherapy: a multistudy analysis. HEC, RAs
54  2013 A randomised, placebo-controlled, double-blind study of aprepitant in nondrinking women younger than 70 years receiving moderately emetogenic chemotherapy. CR
55  2013 An update on palonosetron hydrochloride for the treatment of radio/chemotherapy-induced nausea and vomiting. 5-HT3RAs, CINV
56  2013 Analysis of aprepitant for prevention of chemotherapy-induced nausea and vomiting with moderately and highly emetogenic chemotherapy. CINV, HEC
57  2013 Review of the efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting in a range of tumor types. HEC
58  2012 Efficacy of aprepitant in patients with advanced or recurrent lung cancer receiving moderately emetogenic chemotherapy. CINV, CTCAE, PFS
59  2012 Identification of a novel marker associated with risk for delayed chemotherapy-induced vomiting. 5-HIAA
60  2012 Palonosetron plus 1-day dexamethasone for the prevention of nausea and vomiting due to moderately emetogenic chemotherapy: effect of established risk factors on treatment outcome in a phase III trial. AC, CINV
61  2012 Single-dose intravenous casopitant in combination with ondansetron and dexamethasone for the prevention of oxaliplatin-induced nausea and vomiting: a multicenter, randomized, double-blind, active-controlled, two arm, parallel group study. CINV, CR
62  2012 [Efficacy of aprepitant for quality of life of outpatients receiving moderately emetogenic chemotherapy]. FLIE, QOL
63  2011 Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). AC, HEC, HEC and MEC
64  2011 Palonosetron in combination with 1-day versus 3-day dexamethasone for prevention of nausea and vomiting following moderately emetogenic chemotherapy: a randomized, multicenter, phase III trial. AC, CINV, CR
65  2011 Palonosetron versus other 5-HT₃ receptor antagonists for prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies treated with emetogenic chemotherapy in a hospital outpatient setting in the United States. CINV, HEC, RAs
66  2011 Perception of healthcare providers versus patient reported incidence of chemotherapy-induced nausea and vomiting after the addition of NK-1 receptor antagonists. CINV, HEC
67  2011 Single-dose palonosetron and dexamethasone in preventing nausea and vomiting induced by moderately emetogenic chemotherapy in breast and colorectal cancer patients. BC, CINV, CR, CRC
68  2011 Single-dose palonosetron for prevention of chemotherapy-induced nausea and vomiting in patients with aggressive non-Hodgkin's lymphoma receiving moderately emetogenic chemotherapy containing steroids: results of a phase II study from the Gruppo Italiano per lo Studio dei Linfomi (GISL). CC, CR, GISL
69  2010 Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: a randomized, double-blind study. AC, CINV
70  2010 Aprepitant: drug-drug interactions in perspective. CYP3A4
71  2010 The efficacy of oral ondansetron and dexamethasone for the prevention of acute chemotherapy-induced nausea and vomiting associated with moderately emetogenic chemotherapy - a retrospective audit. CINV
72  2009 A phase II dose-ranging study of palonosetron in Japanese patients receiving moderately emetogenic chemotherapy, including anthracycline and cyclophosphamide-based chemotherapy. CINV, CR, RAs
73  2009 Aprepitant: a review of its use in the prevention of nausea and vomiting. CINV, HEC, PONV
74  2009 Palonosetron: in the prevention of nausea and vomiting. CINV, HEC, PONV
75  2009 Phase 2 trial results with the novel neurokinin-1 receptor antagonist casopitant in combination with ondansetron and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting in cancer patients receiving moderately emetogenic chemotherapy. CINV, CR, SN
76  2009 Phase III trial of casopitant, a novel neurokinin-1 receptor antagonist, for the prevention of nausea and vomiting in patients receiving moderately emetogenic chemotherapy. AC
77  2008 Cost-effectiveness analysis of aprepitant in the prevention of chemotherapy-induced nausea and vomiting in Belgium. CINV, QALYs
78  2008 Efficacy of tropisetron in patients with advanced non-small-cell lung cancer receiving adjuvant chemotherapy with carboplatin and taxanes. NSCLC
79  2008 Oral ondansetron is highly active as rescue antiemetic treatment for moderately emetogenic chemotherapy: results of a randomized phase II study. ---
80  2007 A phase II trial of olanzapine, dexamethasone, and palonosetron for the prevention of chemotherapy-induced nausea and vomiting: a Hoosier oncology group study. CINV, HEC
81  2005 Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. APR, CR, DEX, OND